What it is
This is one vial containing two compounds together: 12.5 mg of GLP3-R and 2.5 mg of Cagrilintide, which is 15 mg of peptide in the vial altogether. The ratio is fixed at 1 mg of GLP3-R to 200 micrograms of Cagrilintide, so you cannot adjust one without adjusting the other. (A microgram, or mcg, is one thousandth of a milligram.)
That fixed ratio is the reason for the main warning. Cagrilintide is extremely potent and must be introduced "low and slow". Because the two rise and fall together, anyone already established on GLP3-R has to drop back to a 1 mg GLP3-R dose while getting used to the Cagrilintide.
So the blend is only appropriate if you are new to GLP3-R, or if you are not transferring from a high dose of another GLP. If you are already established on GLP3-R, buy the two peptides separately rather than use the blend.
What the two are, briefly. GLP stands for glucagon-like peptide, a hormone your gut releases when you eat; a GLP compound copies it and switches on the same receptors, which suppresses appetite. Cagrilintide copies amylin, a different hormone that the pancreas releases alongside insulin, which controls appetite, fullness, and blood sugar. Because they work on separate pathways, their effects add up.
It comes as a dry powder in a sealed vial. You add bacteriostatic water — sterile water with a preservative — then inject just under the skin, a subcutaneous injection, once every seven days.
The second component is sometimes spelled "Cagrilinitide"; the correct spelling is Cagrilintide.
A fixed co-formulation of 12.5 mg GLP3-R and 2.5 mg cagrilintide, 15 mg of total peptide per vial — a 1 mg : 200 mcg ratio that cannot be decoupled.
That coupling is the whole clinical caveat. Cagrilintide requires low-and-slow introduction; because the ratio is fixed, an established GLP3-R user must drop to a 1 mg GLP3-R dose to accommodate the amylin arm. The blend is therefore restricted to GLP3-R-naive users, or users not transitioning from a high dose of another GLP; established users should use separate vials.
The two arms are mechanistically distinct — incretin and amylin — which is why they combine additively rather than competing for receptor occupancy.
The blend is explicitly a starter vehicle, not a maintenance one. The plan is one blend vial, then a transition to separate vials, because GLP3-R and cagrilintide cannot be run together indefinitely: extended cagrilintide exposure produces anti-cagrilintide antibodies. On separate vials the cagrilintide dose is placed midway between the last and next GLP dose, which sustains appetite suppression and the other benefits across the whole week rather than letting them trough.
No blend-specific benefit, side-effect, or contraindication data is available. See the standalone GLP3-R and Cagrilintide pages.
The amylin component is sometimes misspelled "Cagrilinitide".
What it does
There is no published description of the combination's effects beyond the two components and the ratio between them.
For what each component does, see the Cagrilintide page — appetite suppression, satiety, slowed stomach emptying, blood sugar control, circulation, and bone — and the GLP3-R page.
One functional point is clear: appetite suppression from the blend is what you evaluate at week 4 and again at week 8 to decide whether to increase the dose.
No effect or mechanism data is available for the combination itself. Refer to the standalone Cagrilintide entry for the amylin arm's documented actions; no effect data is available for GLP3-R on its own either.
The only functional endpoint is appetite suppression, used as the titration decision criterion at weeks 4 and 8.
The one substantive pharmacological point is durability: the two cannot be co-administered indefinitely because of anti-cagrilintide antibody formation, and the separate-vial regimen exists to allow the cagrilintide arm to be cycled while the GLP arm continues. Placing the cagrilintide dose midway between GLP doses is described as sustaining appetite suppression and the other benefits throughout the entire week.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- No benefits have been documented for the blend itself. What is covered here is the ratio, the dosing schedule, and the transition to separate vials.Anecdotal
- The one effect it names is appetite suppression, which you use to judge whether to increase the dose at week 4 and week 8.Limited human data
- See the Cagrilintide page for that component's documented benefits.Anecdotal
- No blend-specific benefit data is available.Anecdotal
- Appetite suppression is the only named endpoint, used as the titration decision criterion at weeks 4 and 8.Limited human data
- Refer to the standalone Cagrilintide entry for the amylin arm's outcome data.Anecdotal
Reconstitution and dosing
Mix the vial with 1.5 mL of bacteriostatic water — sterile water with a preservative, so it keeps for weeks. The vial holds 15 mg of peptide in total (12.5 mg of GLP3-R plus 2.5 mg of Cagrilintide), which works out to 100 mcg of blend per unit on the syringe.
Dose once every 7 days. You may dose at any time of day or night, though picking a time you can stick to week after week is preferred. You do not have to be fasted. Cycling of this blend is recommended.
Stay on each dose for a minimum of four weeks, whether or not you are making progress in that period.
Initial dose, weeks 1–4: 12 units, which delivers 1 mg of GLP3-R and 200 mcg of Cagrilintide — 1.2 mg of blend drawn — once every 7 days, for at least four weeks. ("Units" means the marks on an insulin syringe; 100 units is 1 mL.)
After week 4's dose, look at your progress. If you are not having severe side effects and you are getting satisfactory appetite suppression at the initial dose, stay there until it is well tolerated and the appetite suppression starts to fade. Then move up.
Second dose, weeks 5–8 or later: 36 units, which delivers 3 mg of GLP3-R and 600 mcg of Cagrilintide — 3.6 mg of blend drawn — once every 7 days, for at least four weeks. Make the same evaluation after week 8's dose.
Moving to separate vials. If you increase at week 5, you will finish the blend vial at week 7. From there, switch to using GLP3-R and Cagrilintide in separate vials. The reason is that the body builds antibodies against Cagrilintide if you run it too long, so it needs to be cycled on and off independently — which a fixed blend cannot do.
On separate vials, keep your normal GLP3-R schedule and take the Cagrilintide dose midway between your last and next GLP dose. That keeps appetite suppression and the other benefits steady across the whole week instead of dipping.
Reconstitute in 1.5 mL of bacteriostatic water. Vial total 15 mg (12.5 mg GLP3-R + 2.5 mg cagrilintide), so 10 mg/mL of blend — 100 mcg of blended peptide per insulin unit, comprising 83.3 mcg GLP3-R and 16.7 mcg cagrilintide. Doses are specified per component; the schedule below carries the total blend mass drawn, with the component split in the row label. Computed against the 15 mg vial total, 1.2 mg of blend is 12 units (1 mg GLP3-R / 200 mcg cagrilintide) and 3.6 mg of blend is 36 units (3 mg / 600 mcg).
Once every 7 days; any time of day, consistency preferred; fasting not required; cycling recommended. Minimum four weeks at each dose regardless of progress.
Initial dose weeks 1–4: 12 units (1 mg GLP3-R / 200 mcg cagrilintide). Second dose weeks 5–8 or later: 36 units (3 mg / 600 mcg). At each four-week checkpoint the escalation gate is twofold — no severe adverse effects and appetite suppression having waned. If suppression is still satisfactory, hold rather than escalate.
Exit strategy is part of the protocol, not an afterthought. Escalating at week 5 exhausts the blend vial at week 7. From there, transition to separate vials so the cagrilintide arm can be cycled off independently, since anti-cagrilintide antibodies form with prolonged exposure. On separate vials, hold the normal GLP3-R schedule and place the cagrilintide dose midway between GLP doses — this converts the weekly trough in appetite suppression into a staggered two-agent coverage across the full seven days.
The ratio constraint bears repeating: at 1 mg GLP3-R : 200 mcg cagrilintide, an established GLP3-R user at 6 mg or above cannot use this vial without a substantial GLP dose reduction. Separate vials are the correct route in that case.
12.5/2.5 mg blend vial (15 mg total peptide) — 12.5 mg GLP3-R + 2.5 mg Cagrilintide
Mix with 1.5 mL of bacteriostatic water, giving 10 mg/mL of blend — 100 mcg of blended peptide per insulin unit. The vial holds 15 mg of peptide in total: 12.5 mg GLP3-R and 2.5 mg Cagrilintide. Doses are specified per component, so the doses below are the total blend drawn, with the GLP3-R and Cagrilintide split given in each row label. These draws come to 12 units and 36 units.
10 mg/mL · 100 mcg per unit
Cycle: Cycling of this blend is recommended. One blend vial, then transition to separate GLP3-R and Cagrilintide vials · Frequency: Once every 7 days; minimum 4 weeks at each dose whether or not you are making progress; any time of day or night, a consistent time preferred; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| Initial dose, weeks 1–4 — 1 mg GLP3-R + 200 mcg Cagrilintide (1.2 mg of blend drawn) | 1.2 mg | 12 units | once every 7 days |
| 2nd dose, weeks 5–8 or later — 3 mg GLP3-R + 600 mcg Cagrilintide (3.6 mg of blend drawn) | 3.6 mg | 36 units | once every 7 days |
15 mg of blend in 1.5 mL is 10 mg/mL, or 100 mcg per unit. Draw 12 units (0.12 mL) for 1.2 mg of blend.
- GLP3-R1 mg
- Cagrilintide200 mcg
Who should avoid it
- No contraindications have been documented for the blend itself. That is a gap in the available information, not a statement that there are none — see the Cagrilintide page and the GLP1-S / Cagrilintide blend page, whose lists apply to the Cagrilintide component.
- Anyone already established on GLP3-R should not use the blend. Because the ratio is fixed, it would force you down to a 1 mg GLP3-R dose. Buy the two peptides separately instead.
- Anyone transferring from a high dose of another GLP should not use the blend, for the same reason.
- Do not run the two together indefinitely. Extended use leads the body to make antibodies against Cagrilintide, which may reduce its effect. The plan is one blend vial, then separate vials.
- Talk to a doctor before starting.
- No blend-specific contraindications documented. The Cagrilintide and GLP1-S / Cagrilintide blend pages carry lists that apply to the amylin component.
- Established GLP3-R users: the fixed 1 mg : 200 mcg ratio forces a drop to 1 mg GLP3-R. Use separate vials.
- Users transitioning from a high dose of another GLP: same constraint.
- Indefinite co-administration is ruled out by anti-cagrilintide antibody formation. One blend vial, then separate vials with the cagrilintide arm cycled.
Side effects
- No side effects have been documented for the blend itself. That is a gap in the available information rather than a statement that none occur.
- See the Cagrilintide page for that component's side effect list — injection site reactions, nausea, vomiting, constipation, fatigue, headache, diarrhoea, heartburn, and rarely gallbladder stones.
- 'Severe adverse side effects' are a reason to hold rather than increase your dose at the week 4 and week 8 checkpoints, without naming which.
- No blend-specific side-effect data is available.
- Refer to the standalone Cagrilintide entry for the amylin arm's documented profile.
- 'Severe adverse side effects' act as a gate on escalation at the week 4 and week 8 evaluation points, without enumerating them.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The recommended next step after finishing one blend vial: buy the two separately so you can cycle the Cagrilintide on and off while keeping your GLP3-R schedule.
The intended successor regimen. Maintain the standard GLP3-R weekly schedule at whatever dose was reached, decoupled from the amylin arm.
On separate vials, take the Cagrilintide dose midway between your last and next GLP3-R dose. That keeps appetite suppression steady across the whole week.
Dosed at the midpoint of the GLP interval to fill the trough. Also allows cycling the amylin arm off before anti-cagrilintide antibodies develop — the constraint the fixed blend cannot accommodate.
Dosing figures have been reviewed and units are recomputed from the stated protocol.